Get it on Google Play

Gilead's Livdelzi hits ALP normalization in Phase 3 PBC trial

November 5, 2026 10:00 AM EST Send to a Friend
Gilead Sciences (NASDAQ: GILD) announced results from its Phase 3 IDEAL study showing that 75.4% of participants with primary biliary ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login